Also trades as: NAMS (NASDAQ) · $vol 31M
NAMSW NASDAQ
NewAmsterdam Pharma Company N.V.
1W: +0.0%
1M: +23.0%
3M: +5.2%
YTD: +18.2%
1Y: +212.5%
3Y: +1042.7%
5Y: +2727.1%
$24.26
-3.05 (-11.17%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$2.8B
52W Range7.155-30.45
Volume200
Avg Volume1,163
Beta0.03
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichael Harvey Davidson Facp.
Employees68
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-10
Websitenewamsterdampharma.com
Gooimeer 2-35
Naarden 1411 DC
NL
Naarden 1411 DC
NL
31 35 206 2971
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Latest News
New ethics reports reveal thousands of stock trades made in President Trump’s name so far this year - Scripps News
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
Do NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses?
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| LANGE LOUIS G | S-Sale | 44,173 | $30.41 | 2026-03-11 |
| LANGE LOUIS G | S-Sale | 446 | $31.23 | 2026-03-11 |
| LANGE LOUIS G | X-InTheMoney | 44,619 | $11.50 | 2026-03-09 |
| LANGE LOUIS G | X-InTheMoney | 44,619 | $11.50 | 2026-03-09 |
| Kastelein Johannes J | M-Exempt | 101,409 | — | 2026-03-09 |